UCSF

Akinyemi Oni-Orisan, PharmD, PhD

Assistant Professor
Department of Clinical Pharmacy
Oni-Orisan
Myra Gloria
[email protected]
Phone: +1 415 502-7551
Fax: +1 415 476-1356
513 Parnassus Avenue, Rm 966B
UCSF Box 0794
San Francisco, CA 94143
United States

Links

UCSF Profiles

What I do

My lab conducts computational research investigating therapies for cardiovascular disease using observational data from electronic health records. I also teach pharmacy students in the Discovery Projects research program including leading the Health Disparities Discovery Group and serving as a primary mentor for students in the Pharmacogenomics Discovery Group.

Departmental research area

clinical research

My research expertise

pharmacogenomics, pharmacoepidemiology, pharmacometrics, electronic health records

Clinical expertise

cardiovascular disease risk reduction, lipid management

Degrees

PhD, Pharmacotherapy and Experimental Therapeutics, University of North Carolina
PharmD, University of Michigan
BS, Biology, University of Michigan

Research keywords

pharmacogenomics, health disparities, Cardiovascular drugs, Adrenergic beta-Antagonists, Amino Acid Substitution, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Eicosanoids, Myocardial Reperfusion Injury, Epoxide Hydrolases, Arachidonic Acids, Prostaglandin-Endoperoxide Synthases, Cholesterol, LDL, Arachidonic Acid, pharmacogenetics, Cardiotonic Agents, Cytochrome P-450 Enzyme System, Acute Coronary Syndrome, Electronic Health Records

Publications

Embracing Genetic Diversity to Improve Black Health. N Engl J Med. 2021 Feb 10.
Oni-Orisan A, Srinivas N, Mehta K, Lohy Das J, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA. Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. Clin Transl Sci. 2021 Jan 09.
Scott R. Bauer, Benjamin N. Breyer, Akinyemi Oni-Orisan, Michael A. Steinman, Ida Sim, Charles E. McCulloch, Stacey A. Kenfield. PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms. Frontiers in Digital Health. 2020 Jun 26; 2:7.
Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ. The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom Med. 2020; 5:1.
Fohner AE, Ranatunga DK, Thai KK, Lawson BL, Risch N, Oni-Orisan A, Jelalian AT, Rettie AE, Liu VX, Schaefer CA. Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system. Pharmacogenet Genomics. 2019 10; 29(8):192-199.
Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circ Genom Precis Med. 2018 09; 11(9):e002043.
Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR. Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. Prostaglandins Other Lipid Mediat. 2018 09; 138:15-22.
Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics. 2018 06 01; 19(9):771-782.
Akinyemi Oni-Orisan, Thomas Hoffmann, Marisa Medina, Eric Jorgenson, Catherine Schaefer, Ronald Krauss, Carlos Iribarren, Neil Risch. Validation of Electronic Health Records for the Assessment of Statin Dosing In Research. Journal of Clinical Lipidology. 2017 May 1; 11(3):836-837.
Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. J Clin Invest. 2017 Feb 01; 127(2):670-680.
Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res. 2016 Jan; 57(1):109-19.
Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014 Sep-Oct; 22(5):193-8.
Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol. 2014 Sep; 74:199-208.
Acute decompensated heart failure: evolving literature and implications for future practice. Pharmacotherapy. 2014; 34(4):373-88.
Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:67-73.
Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab. 2012 Mar 01; 302(5):E500-9.
Make a gift
We see a time when precise therapeutics—used safely and effectively—improve the health of people everywhere.
© 2002–2021 The Regents of the University of California